MRVI Q4 2025 Earnings — Maravai LifeSciences Holdings, Inc. Revenue & Financial Results | Market Cap Arena

MRVIMaravai LifeSciences Holdings, Inc.

$999M

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$50M-11.6% YoY

Gross Profit

$12M24.5% margin

Operating Income

-$7M-13.5% margin

Net Income

-$36M-71.6% margin

EPS (Diluted)

$-0.25

QoQ Revenue Growth

+19.8%

Cash Flow

Operating Cash Flow

-$23M

Free Cash Flow

-$25M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$771M

Total Liabilities

$398M

Stockholders' Equity

$212M

Cash & Equivalents

$217M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$56M	-11.6%
Gross Profit	$12M	$19M	-35.4%
Operating Income	-$7M	-$38M	+82.3%
Net Income	-$36M	-$26M	-36.5%

Geographic Segments

North America

$27M55%

Asia Pacific

$14M29%

EMEA

$8M15%

Latin And Central America

$324,0001%